FLT3 is a commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome suggesting a possible future role for treatment of AML.
Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in phase I-II clinical trials. CTI has exclusive marketing and co-development rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North, Central and South America.
About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert Media Contact: Dan Eramian T: 206.272.4343C: 206.854.1200E: firstname.lastname@example.org www.CellTherapeutics.com/press_room
Investors Contact: Ed BellT: 206.282.7100 Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: email@example.com www.CellTherapeutics.com/investors Medical Information Contact:T: 800.715.0944E: firstname.lastname@example.org SOURCE Cell Therapeutics, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts